-
Sustained R&D productivity has generated 14 clinical development
candidates against 11 discrete molecular targets
-
Diverse immuno-oncology and targeted cancer therapy portfolios
comprised of both large and small molecule therapies
-
Live webcast presentation from AACR taking place Sunday, April 17,
2016 at 7:00 p.m. CDT / 8:00 p.m. EDT
Incyte Corporation (Nasdaq: INCY) will highlight the productivity of its
drug discovery and development organization and aspects of its
development portfolio at an investor event on Sunday, April 17, 2016 at
the American Association for Cancer Research (AACR) Annual Meeting 2016
in New Orleans, Louisiana.
The event will include a discussion of Incyte’s second-generation PI3Kδ
inhibitor, INCB50465; the Company’s immuno-oncology portfolio, including
its anti-GITR antibody, INCAGN1876, anti-OX40 antibody, INCAGN1949, and
emerging data with its small molecule BRD inhibitor, INCB54329; as well
as its targeted epigenetic therapies, including a novel LSD1 inhibitor
entering Phase 1 development, INCB59872.
“Incyte operates with the conviction that investment in basic research
can translate into innovative therapies that can address important unmet
medical needs. To that end, we are pleased to be able to highlight such
a broad collection of abstracts from our emerging development portfolio
at this year’s AACR Annual Meeting,” stated Reid Huber, Ph.D., Incyte’s
Chief Scientific Officer. “The research team’s productivity is a result
of the quality of our scientific organization and the efficiency of our
R&D model.”
As part of its succession plan, Incyte also announced that after almost
13 years at the Company, Dr. Richard Levy, Chief Drug Development
Officer, is retiring effective April 30, 2016. Dr. Steven Stein,
Incyte’s Chief Medical Officer, will now assume all of Dr. Levy’s
responsibilities. Dr. Levy was instrumental in building the broad and
diverse portfolio Incyte has today, and developing Jakafi®
(ruxolitinib), the Company’s proprietary JAK 1/JAK 2 inhibitor.
Webcast Information
The investor event will be webcast live on Sunday, April 17, 2016
at 7:00 p.m. CDT / 8:00 p.m. EDT and can be accessed via the Investor’s
section of www.incyte.com
under “Events and Presentations.” Investors interested in listening to
the live webcast should log-on before the start time to download any
required software. The presentation slides will also be made available
following the event.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical
company focused on the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte, please
visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set
forth in this press release, including statements regarding the
Company’s development pipeline and the potential of the Company’s
product candidates, contain predictions, estimates and other
forward-looking statements. These forward-looking statements are based
on the Company’s current expectations and subject to risks and
uncertainties that may cause actual results to differ materially,
including unanticipated developments and the risks related to the
efficacy or safety of the Company’s development pipeline, the results of
further research and development, the high degree of risk and
uncertainty associated with drug development, clinical trials and
regulatory approval processes, other market or economic factors and
competitive and technological advances; and other risks detailed from
time to time in the Company’s reports filed with the Securities and
Exchange Commission, including its Form 10-K for the year ended December
31, 2015. Incyte disclaims any intent or obligation to update these
forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160415005875/en/
Copyright Business Wire 2016